Lexicon Pharmaceuticals (LXRX) Stock Price, Quote, News & History | Benzinga

SPY779.87 QQQ759.84+0.02%BTC/USD84,034.12−1.77%DIA514.66 GLD381.90−0.10%TLT77.20−0.10%

Lexicon Pharmaceuticals Inc (LXRX) Stock Price, Quote, News & History

LXRXNASDAQ

Trade with Public

Trade with Public

$1.75

0.010.57%

Last update: Oct 6, 5:56 PM

$1.78

0.042.3%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$1.75

Volume / Avg.

0 / 2.93M

Day Range

- - -

52 Wk Range

1.10 - 2.68

Market Cap

$792.02M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

34

Short Interest

12.19%

Days to Cover

13.4

Recent Lexicon Pharmaceuticals, Inc. News

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).

Avi Kapoor

Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.

Avi Kapoor

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.

Avi Kapoor

Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.

Avi Kapoor

Gold Tumbles Over 6%; Apple Posts Upbeat Earnings

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-64.99M

Investing Cash Flow (TTM)

-29.77M

Financing Cash Flow (TTM)

85.32M

Free Cash Flow (TTM)

-64.99M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-9.44M

Analyst Trends and Forecast

1

May

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$647.34M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

16.51

PB Ratio (TTM)

4.46

Earnings Yield % (TTM)

-9.14%

Earnings Yield % (FWD)

-11.43%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.39

Company Debt

Total Debt

$51.44M

LT Debt

$51.44M

LT Debt Issuance (TTM)

$55.00M

LT Debt Repayment (TTM)

-$62.26M

Total Cash

$40.92M

Debt to Equity

0.34

Issuance of Debt (TTM)

-$7.26M

Repayment of Debt (TTM)

-$62.26M